Pennsylvania's largest health system, Jefferson Health, has taken pharmaceutical giants and pharmacy benefit managers to court over the skyrocketing cost of insulin. The lawsuit claims that these powerful corporations have conspired to artificially inflate the prices of this life-saving medication, prioritizing profits over patient needs.
The case centers around three major insulin manufacturers โ Eli Lilly, Novo Nordisk, and Sanofi โ whose prices have risen by over 1,000% since the 1990s. In contrast, a one-month supply of Ozempic was priced at $936 in the US in 2023, whereas it cost just $147 in Canada and $83 in France.
Jefferson Health is seeking financial compensation not only for its own insulin costs but also as a major employer with over 58,000 workers who rely on diabetes medication. The lawsuit accuses these corporations of colluding to artificially raise prices "far beyond inflation," despite the low production costs of insulin.
The health system's complaint comes on the heels of similar lawsuits from cities like Philadelphia and over 550 state and local governments, companies, and unions, all seeking damages for alleged price gouging. Jefferson's case was filed in a New Jersey court as part of this broader litigation.
Insulin prices have long been a contentious issue, with many patients struggling to afford the medication they need. This lawsuit aims to hold accountable those responsible for driving up these costs, highlighting the need for greater transparency and regulation in the pharmaceutical industry.
The case centers around three major insulin manufacturers โ Eli Lilly, Novo Nordisk, and Sanofi โ whose prices have risen by over 1,000% since the 1990s. In contrast, a one-month supply of Ozempic was priced at $936 in the US in 2023, whereas it cost just $147 in Canada and $83 in France.
Jefferson Health is seeking financial compensation not only for its own insulin costs but also as a major employer with over 58,000 workers who rely on diabetes medication. The lawsuit accuses these corporations of colluding to artificially raise prices "far beyond inflation," despite the low production costs of insulin.
The health system's complaint comes on the heels of similar lawsuits from cities like Philadelphia and over 550 state and local governments, companies, and unions, all seeking damages for alleged price gouging. Jefferson's case was filed in a New Jersey court as part of this broader litigation.
Insulin prices have long been a contentious issue, with many patients struggling to afford the medication they need. This lawsuit aims to hold accountable those responsible for driving up these costs, highlighting the need for greater transparency and regulation in the pharmaceutical industry.